±zªºÂsÄý¾¹¤£¤ä´© VB/JavaScript»yªk,¦ý¬O¨Ã¤£¼vÅT±zÀò¨ú¥»ºô¯¸ªº¤º®e,½Ð¦Û¦æ¿é¤J¥¿½Tªº¸ê®Æ
Logo Logo
¦rÅé ¤p«¬¦rÅé ¤¤«¬¦rÅé ¤j«¬¦rÅé
ÁcÅ餤¤å ¥þ²y¸ê°Tºô-²Å餤¤å ¥þ²y¸ê°Tºô-English
»{ÃÑ¥ú¥Ð ÂåÀøªA°È ±¾¸¹ªA°È ½Ã±Ð¤Ñ¦a ¯f±w¶·ª¾ ±Ð¾Ç¬ã¨s ¦^­º­¶

¸Ë¹¢¥Î¹Ï¤ù
ÂåÀøªA°È³æ¤¸¹Ï¤ù
¬ì§O¤¶²Ð


ªù¶E³B¤è¥ÎÃĬd¸ß
¯S¦âÂåÀø
:::¸Ë¹¢¥Î¹Ï¤ù
¥»ºô­¶¸ê®Æ¶È¨Ñ°Ñ¦Ò¡A¦p¦³ºÃ°Ý©Î¿ù»~½Ð¤´¨Ì¼t°Ó¸ê®Æ¬°¥D¡C
Âå¥O½X 22279 °·«O½X BC21545414
°Ó«~¦W TIMOPTOL XE 0.5% 2.5ML/50drops ÃÄ«~³\¥iÃÒ ½Ã¸pÃÄ¿é¦r²Ä021545¸¹
¤¤¤å¦W «C²´ÅSªø®Ä«¬ÂI²´²G¾¯ °·«O§½ÃIJzÃþ§O 524008 £]-adrenergic agents
¾Ç¦W Timolol ¥~Æ[´y­z
¥~Æ[¹Ï¥Ü
Ãþ§O POUT ¾¯¶q DROP
§Ü¥Í¯À ºÞ¨îÃÄ
¥é³æ TIMOPTOL XE 0.5%
¥ÎÃÄ«ü¾É³æ±i
ATC7ÃIJzÃþ§O S01ED01 timolol
¥¥°ü¥ÎÃĤÀ¯Å C ¯Å¡G
¦b¹ï·Óªº°Êª«¬ã¨s¸ÕÅ礤Åã¥Ü¸ÓÃľǪ«¹ï­F­L¦³¤£¨}¤ÏÀ³¡]­P·î­L©Ê©Î±þ­F­L©Ê©Î¨ä¥L¡^¡A¦ý¥¼¶i¦æ¤HÅéÃh¥¥°ü¤k¬ã¨s¡F©ÎªÌ©|µL¹ï·Óªº¤HÅéÃh¥¥°ü¤k©Î°Êª«¬ã¨s¸ÕÅç¡C¥u¦³¦b¥i¯àªº§Q¯q¤j©ó¼ç¦bªº¦MÀI¡A¤~¥i¨Ï¥Î¦¹ÃĪ«¡C

µ²ºc¦¡
(S)-Timolol maleate C13H24N4O3S.C4H4O4 [26921-17-5]
UpToDate UpToDate ³sµ²
ÃIJz§@¥Î
Timolol¡G¬O¤A«¬-1©M¤A«¬-2 («D¿ï¾Ü©Êªº)ªºµÇ¤W¸¢¯À±µ¨üÅéªýÂ_¾¯¡A¤£¨ã¦³©úÅ㪺¤º¥Í©ÊÀÀ¥æ·P¯«¸g¾¯¡Bª½±µ¤ß¦Ù§í¨î¾¯©Î§½³¡³Â¾K¾¯¡]½¤Ã­©w¡^µ¥ÃþÃÄ«~ªº¬¡©Ê¡CTimololÂǥѴî¤ÖÅÖ¤ò¤W¥Ö²Ó­M§Î¦¨©Ð¤ôªº§@¥Î¨Ó­°§C²´¤ºÀ£¡C¥Ø«e¨Ã¤£²M·¡timolol­°§C²´¤ºÀ£ªº¯u¥¿§@¥Î¾÷Âà¡A¦ý¥i¯à¬O¨Ï¦]¤º¥Í©Ê¤A«¬µÇ¤W¸¢¯À¨ë¿E§@¥Î¦Ó¼W¥[¦X¦¨cAMPªº±¡§Î¨ü¨ì§í¨î¡CTimolol¨Ã¤£·|©úÅã¼vÅT¦å²G-©Ð¤ô«Ì»Ù»P¦å¼ß³J¥Õ¶¡ªºº¯³z©Ê¡C
¾AÀ³¯g
°ª²´À£¯g¡A¼s¨¤©Ê«C¥ú²´¡C
¥Îªk¥Î¶q
±`¥Î°_©l¾¯¶q¬°0.25% TIMOPTOL-XEºw©ó±w²´¤@ºw¡A¤@¤é¤@¦¸¡A­YÁ{§É¤ÏÀ³¤£¨Î®É¡A¥i§ï¥H0.5% TIMOPTOL-XEºw©ó±w²´¤@ºw¡A¤@¤é¤@¦¸¡C¨Ï¥Î«e±N²~¤l¤ÏÂஶ·n¤@¦¸¡A¦ýµL»Ý®¶·n¶W¹L¤@¦¸¡C
¥²­n®É¡ATIMOPTOL-XE¥i¨Ö¥Î¨ä¥LÃÄ«~¥H­°§C²´¤ºÀ£¡A¦ý¤£«Øij¦P®É¨Ï¥Î¨âºØ¤A«¬µÇ¤W¸¢¯ÀªýÂ_¾¯ªvÀø(¨£ª`·N¨Æ¶µÄæ)¡C­Y©M¨ä¥L²´¥Î»s¾¯¨Ö¥Î®É¡A»Ý¥ý§ë»P¨ä¥L²´¥Î»s¾¯¡A¦Ü¤Ö¶¡¹j¤Q¤ÀÄÁ¥H¤W¡A¦A§ë»P¥»«~¡C
ÃİʤO¾Ç
1.µ¹¤©TIMOPTOL-XE¡A¦b2-4¤p®É¤º²£¥Í³Ì¤jªº­°²´À£®ÄªG¡A0.25%©M0.5% TIMOPTOL-XE§¡¯àºû«ù24¤p®É©úÅ㪺­°²´À£§@¥Î¡C
2.Timolol maleateªº°_©l§@¥Î§Ö³t¡A¬ù¦b§½³¡µ¹ÃÄ«á20¤ÀÄÁ²£¥Í§@¥Î¡C
°Æ§@¥Î
±`¨£ªºÃÄ«~¬ÛÃö°Æ§@¥Î¬°µ¹ÃÄ«á«ùÄò30¬í¦Ü5¤ÀÄÁªº¼È®É©Êµø¤O¼Ò½k(6%)¡C
¥æ¤¬§@¥Î

Clonidine
May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal.

Epinephrine
Initial hypertensive episode followed by bradycardia may occur.

Ergot derivatives
Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur.

Insulin
Prolonged hypoglycemia with masking of symptoms may occur.

NSAIDs
Some agents may impair antihypertensive effect.

Prazosin
Orthostatic hypotension may be increased.

Theophyllines
Elimination of theophylline may be reduced. Effects of both drugs may be reduced.

Verapamil
Effects of both drugs may be increased.

¸T§Ò
1.¹ï©ó±w¦³¤ÏÀ³©Ê®ð¹D¯e¯f¡B®ð³Ý©Î¦³®ð³Ý¯f¥v©ÎÄY­«ªººC©Êªý¶ë©ÊªÍ³¡¯e±w¯f¯gªÌ¡CƒÜ
2.Äu©Ê¤ß·i¹LºC¡FÄu©Ð¶Ç¾Éªýº¢¡F¤G«×©Î¤T«×©Ð«Ç¶Ç¾Éªýº¢¡F©úÅã¤ß°IºÜ¡F¤ß¦]©Ê¥ð§J¡CƒÜ
3.¹ï¥»«~¦¨¤À¹L±ÓªÌ
µ¹¥I³W©w
14.1.°ª²´À£¤Î«C¥ú²´²´¥Î»s¾¯(101/12/1¡B102/8/1¡B104/4/1¡B106/2/1¡B110/5/1)
¥»ÃþÃĪ«Àøµ{¾¯¶q¦p¤U¡G(106/2/1)
1.¦h¦¸¨Ï¥Î¥]¸Ë(³W®æ¶q¡Ù2.5mL):
(1)³æ²´¨C4¶g³B¤è¬°1²~¡AÂù²´±o¨C2¶g©Î3¶g³B¤è1²~¡C(101/12/1¡B102/8/1¡B104/4/1)
2.³æ¦¸¨Ï¥Î¥]¸Ë(¤£§t¨¾»G¾¯)¡A³æ²´©ÎÂù²´¨C4¶g­­³B¤è¤ä¼Æ¦p¤U(106/2/1)¡G
(1)¨C¤é¨Ï¥Î1¦¸ªÌ¡A­­30¤ä(§t)¥H¤U¡C
(2)¨C¤é¨Ï¥Î2¦¸ªÌ¡A­­60¤ä(§t)¥H¤U¡C
(3)¨C¤é¨Ï¥Î3¦¸ªÌ¡A­­90(§t)¤ä¥H¤U¡C
(4)¨C¤é¨Ï¥Î4¦¸ªÌ¡A­­120(§t)¤ä¥H¤U¡C
3.ªvÀø®É¡A¤£±o¨Ö¥Î¨ä¥L¦PÃþÃÄ«~¡C


14.1.1.³æ¤è»s¾¯(90/10/1¡B101/12/1¡B104/4/1¡B106/2/1)¡G
1.£]-¥æ·P¯«¸gªýÂ_¾¯(£]-blockers )
2.ºÒ»ÄÓþ?§í¨î¾¯(Carbonic anhydrase inhibitor) :
­­¹ï£]-blockers¦³¸T§Ò¡B¤£¾A©Î¨Ï¥Î®ÄªG¤£¨Î¤§¯f±w¨Ï¥Î¡C
3.«e¦C¸¢¯À­l¥Íª«Ãþ¡G
(Prostaglandin analogues)¡G(93/2/1¡B101/12/1)
(1)­­¹ï£]-blockers¨Ï¥Î®ÄªG¤£¨Î©Î¤£¾A¥Î¤§¯f±w¨Ï¥Î¡C©y¥ý¥H³æ¿W¨Ï¥Î¬°­ì«h¡C
(2)Àø®Ä¤´¤£¨¬®É¡A±o¨Ö¥Î¨ä¥L­°²´À£¥ÎÃÄ(§t½Æ¤è»s¾¯)¡C
ª`·N¨Æ¶µ
©M¨ä¥L²´¥Î»s¾¯¤@¼Ë¡A¥»«~¥i¯à¦³¥þ¨­©Ê§l¦¬¡C¤A«¬µÇ¤W¸¢¯ÀªýÂ_¾¯§½³¡µ¹ÃÄ¥ç¥i¯àµo¥Í©M¥þ¨­©Êµ¹ÃĤ@¼Ëªº¤£¨}¤ÏÀ³¡C
ÃÄ«~«O¦s¤è¦¡
»Ý©ó25¢XC¥H¤UÁ×¥úÀx¦s¡AÁקK§N­á

ÂsÄý¤H¼Æ¡G059585888 ¸Ë¹¢¥Î¹Ï¤ù ºô¯¸¾ÉÄý ¸Ë¹¢¥Î¹Ï¤ù ºôºô¬Û³s ¸Ë¹¢¥Î¹Ï¤ù ±ÄÁʤ½§i
  1. ¨F³ÀÁ`°|¡G¥x¤¤¥«¨F³À°Ï¨F¥Ð¸ô117¸¹¡@¹q¸Ü¡G(04)2662-5111
  2. ¤j¥Ò°|°Ï¡G¥x¤¤¥«¤j¥Ò°Ï¸g°ê¸ô321¸¹¡@¹q¸Ü¡G(04)2688-5599
Áô¨pÅv¤Î¸ê°T¦w¥þ¬Fµ¦«Å§i